Loading...
Loading...
TRVI| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 13.3M |
| Operating I/L | -13.3M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.9M |
| Pretax | -12.4M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -12.4M |
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently in phase IIb/III clinical trials for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis. The company generates revenue through the development and commercialization of Haduvio, with a license agreement in place with Endo Pharmaceuticals Inc. to develop and market products containing nalbuphine hydrochloride in any formulation.
